Skip to content
value.today
Pluton Biosciences, LLC logo

Pluton Biosciences, LLC

Formerly Pluton Biosciences, LLC

Total raised
$24 M
2 rounds on record
Latest round
$18 M
Feb 2023
First round on record
Sep 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pluton Biosciences, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2023$18 MNo. 2$10 to $50 million

Pluton Biosciences, LLC: Raise no. 2, Feb 2023

Investors in this round

12 investors had bought by the notice of Jun 2, 2023: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
$75,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Barry Goldman · Executive Officer, Director · Director; Founder; President; Chief Science Officer; Secretary
  • Elizabeth Gallegos · Executive Officer, Director · Director; Chief Executive Officer
  • Charles Lin · Director · Director
  • Clay Mitchell · Director · Director
  • Gerald Steiner · Director · Director
  • Michael Gillespie · Director · Director
  • Neal Gutterson · Director · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds will be used for general working capital, which may include salary payments to executive officers and directors. An estimate of such amount is unknown at this time.”

Signed by Elizabeth Gallegos, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 2, 2023. Read the notice at the SEC.

equitySEC
Sep 2021$7 MNo. 1$2 to $10 million

Pluton Biosciences, LLC: Raise no. 1, Sep 2021

Investors in this round

38 investors had bought by the notice of Oct 1, 2021: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
$10,344
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Missouri

People named in the notice

  • Barry Goldman · Executive Officer, Director
  • Charles Walch · Executive Officer
  • Steven Slater · Executive Officer, Director
  • Clay Mitchell · Director
  • Glendon Schuster · Director
  • Wesley Selke · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds will be used for general working capital, which may include salary payments to executive officers and directors. An estimate of such amount is unknown at this time.”

Signed by Sarah Larson c/o Thompson Coburn LLP, Attorney-in-Fact. Source: SEC Form D, newest notice filed Oct 1, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pluton Biosciences, LLC reported revenue of $476,675 for its fiscal year to 31 December 2020 (filed Apr 2021), up from $19,431 the year before.

    SEC Form C-AR · Apr 2021

  • The direct cost of what it sold was $188,857, so 60% of its revenue was left after those costs.

    SEC Form C-AR · Apr 2021

  • Net loss for the same year: $979,712.

    SEC Form C-AR · Apr 2021

  • Pluton Biosciences, LLC chose not to state its revenue in its newest notice of a funding round (Jun 2023).

    SEC Form D · Jun 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2023

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

No investor of Pluton Biosciences, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 38 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pluton Biosciences, LLC
NameRoleNamed in
Barry GoldmanDirector; Founder; President; Chief Science Officer; SecretaryJun 2023
Elizabeth GallegosDirector; Chief Executive OfficerJun 2023
Charles WalchExecutive officerOct 2021
Steven SlaterExecutive officerOct 2021
Barry GoldmanDirector; Founder; President; Chief Science Officer; SecretaryJun 2023
Charles LinDirectorJun 2023
Clay MitchellDirectorJun 2023
Elizabeth GallegosDirector; Chief Executive OfficerJun 2023
Gerald SteinerDirectorJun 2023
Michael GillespieDirectorJun 2023
Neal GuttersonDirectorJun 2023
Glendon SchusterDirectorOct 2021
Steven SlaterDirectorOct 2021
Wesley SelkeDirectorOct 2021